BeiGene trial investigator Jennifer Brown of Dana-Farber Cancer Institute presents the ALPINE results at ASH on Dec. 13 in New Orleans (Photo: Assistant editor Paul Schloesser for Endpoints News)

December 13, 2022 10:00 AM ESTUpdated 01:06 PM

#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

NEW ORLEANS — As the last six abstracts were presented at the American Society of Hematology on Tuesday, BeiGene sought to establish that its BTK inhibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

#ASH22: BeiGene's BTK in­hibitor shows su­pe­ri­or­i­ty to Ab­b­Vie, J&J block­buster in PFS

Associate Editor

Senior Reporter

Sign up to read this article for free.

#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS